Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Regulus Therapeutics stock had an average target of $8.50, with a low estimate of $7.00 and a high estimate of $11.
Price Target: $8.50 (+4.17%)
Analyst Consensus: Buy
Price Target
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock from 6 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.92
from -0.82
EPS Next Year
-1.08
from -0.92
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | -0.82 | |||
| Avg | -0.92 | -1.08 | |||
| Low | -1.12 | -1.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |